<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bassam A. Hazae</style></author><author><style face="normal" font="default" size="100%">Yetti Hernaningsih</style></author><author><style face="normal" font="default" size="100%">Puspa Wardhani</style></author><author><style face="normal" font="default" size="100%">Fatima Albadwi</style></author><author><style face="normal" font="default" size="100%">Nastasya Nunki</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Abnormalities in Hemostatic Parameters Related to Hemodialysis in End-stage Kidney Pathology: A Narrative Review</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Coagulation</style></keyword><keyword><style  face="normal" font="default" size="100%">End-stage Kidney Disease (ESKD)</style></keyword><keyword><style  face="normal" font="default" size="100%">Hemodialysis</style></keyword><keyword><style  face="normal" font="default" size="100%">Hemostasis</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">October 2024</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">16</style></volume><pages><style face="normal" font="default" size="100%">1223-1230</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;Chronic kidney disease (CKD) is a progressively prevalent global health issue. During the initial phases of the condition, CKD is commonly linked to a tendency for excessive blood clotting. While in the end-stage of disease, patients undergoing hemodialysis have a multitude of hemostatic abnormalities. These include prolonged bleeding time, altered platelet count, prolonged PT and aPTT, elevated FDPs and D-dimer, dysregulated vWF activity, and abnormal thrombin generation. These changes result from a combination of uremic toxicity, endothelial dysfunction, inflammatory states, and the effects of the hemodialysis procedure itself. Understanding these mechanisms is crucial for managing and mitigating the bleeding and thrombotic risks in this patient population. This review aims to systematically investigate the effects of hemodialysis on key hemostasis parameters in CKD patients.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">5</style></issue><work-type><style face="normal" font="default" size="100%">Review Article</style></work-type><section><style face="normal" font="default" size="100%">1223</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Bassam A. Hazae&lt;sup&gt;1&lt;/sup&gt;, Yetti Hernaningsih&lt;sup&gt;2,3,4*&lt;/sup&gt;, Puspa Wardhani&lt;sup&gt;2,3,4,5&lt;/sup&gt;, Fatima Albadwi&lt;sup&gt;6&lt;/sup&gt;, Nastasya Nunki&lt;sup&gt;1,7&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Laboratory Medicine Study Interest, Master Program of Basic Medical Science, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;²Department of Clinical Pathology, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Dr. Soetomo General Academic Hospital, Surabaya, East Java, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;⁴Postgraduate School of Universitas Airlangga, Surabaya, East Java, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;5&lt;/sup&gt;Institute of Tropical Disease, Universitas Airlangga, Surabaya, East Java, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;6&lt;/sup&gt;Master student, Biotechnology and Bioengineering, East China University of Science and Technology, Shanghai, CHINA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;7&lt;/sup&gt;Department of Medical Laboratory Technology, Faculty of Health, Universitas Nahdlatul Ulama Surabaya, Surabaya, INDONESIA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dewi Rochmawati</style></author><author><style face="normal" font="default" size="100%">Puspa Wardhani</style></author><author><style face="normal" font="default" size="100%">Yessy Puspitasari</style></author><author><style face="normal" font="default" size="100%">Tutik Kusmiati</style></author><author><style face="normal" font="default" size="100%">Atika</style></author><author><style face="normal" font="default" size="100%">Hartono Kahar</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Concordance of Sputum and Feces Samples for Detecting Mycobacterium Tuberculosis using Xpert® MTB/RIF Ultra</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Feces AFB test</style></keyword><keyword><style  face="normal" font="default" size="100%">Feces Xpert® MTB/RIF Ultra test</style></keyword><keyword><style  face="normal" font="default" size="100%">Mycobacterium tuberculosis (MTB)</style></keyword><keyword><style  face="normal" font="default" size="100%">rifampicin resistance test</style></keyword><keyword><style  face="normal" font="default" size="100%">Xpert® MTB/RIF Ultra</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">February 2024</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">16</style></volume><pages><style face="normal" font="default" size="100%">167-173</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Introduction:&lt;/strong&gt; Tuberculosis (TB) remains a disease with high morbidity and mortality worldwide, and Indonesia ranks among the countries with the highest TB prevalence. There is a need to develop improved detection tools and explore alternative sample sources beyond sputum. Feces samples are one such nonsputum alternative. Xpert® MTB/RIF Ultra is a novel diagnostic tool used in Indonesia. This study aims to assess the concordance of both sputum and feces samples in detecting Mycobacterium tuberculosis (MTB) using Xpert® MTB/RIF Ultra. &lt;strong&gt;Methods: &lt;/strong&gt;An analytical observational study with a cross-sectional design was conducted on TB subjects at Dr. Soetomo Regional Public Hospital (RSUD Dr. Soetomo), Surabaya, and several community health centers (puskesmas) in Surabaya. Sputum and feces samples were collected from the same subjects. These subjects underwent Feces acid-fast bacilli (AFB) tests, sputum and Feces Xpert® MTB/RIF Ultra tests, and sputum culture tests (considered the gold standard), as well as rifampicin resistance tests for positive cultures. Sensitivity and positive predictive value (PPV) tests were conducted using Medcalc software, and the concordance test employed the Kappa value. &lt;strong&gt;Results:&lt;/strong&gt; The study involved 71 research subjects. The sensitivity of Feces AFB tests, sputum, and Feces Xpert® MTB/RIF Ultra tests was 7.3%, 97.6%, and 97.6%, respectively. The Cohen's Kappa consistency test for Feces AFB tests and sputum culture produced a Kappa value of 0.063 (p &amp;gt; 0.05). The Cohen's Kappa consistency test on sputum and Feces Xpert® MTB/RIF Ultra tests yielded a Kappa value of 0.409 (p &amp;lt; 0.05). The Cohen's Kappa consistency test on sputum and Feces Xpert® MTB/RIF Ultra tests compared with the rifampicin resistance tests resulted in Kappa values of 0.902 and 0.951 (p &amp;lt; 0.05). The CT value of Feces Xpert® MTB/RIF Ultra tests was higher than that of sputum Xpert® MTB/RIF Ultra tests. &lt;strong&gt;Conclusion:&lt;/strong&gt; A concordance exists between the results of sputum and Feces Xpert® MTB/RIF Ultra tests, but no concordance is observed between the results of Feces AFB tests and sputum culture tests. The higher CT value of Feces Xpert® MTB/RIF Ultra tests compared to sputum Xpert® MTB/RIF Ultra tests indicates a lower bacterial load in feces. Feces can be considered a viable alternative sample to sputum for MTB detection using Xpert® MTB/RIF Ultra.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><work-type><style face="normal" font="default" size="100%">Research Article</style></work-type><section><style face="normal" font="default" size="100%">167</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Dewi Rochmawati&lt;sup&gt;1&lt;/sup&gt;, Puspa Wardhani&lt;sup&gt;1,2,3&lt;/sup&gt;, Yessy Puspitasari&lt;sup&gt;1&lt;/sup&gt;, Tutik Kusmiati&lt;sup&gt;4&lt;/sup&gt;, Atika&lt;sup&gt;5&lt;/sup&gt;, Hartono Kahar&lt;sup&gt;1,3&lt;/sup&gt;,*&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Department of Clinical Pathology, Faculty of Medicine, Universitas Airlangga, Dr. Soetomo General Academic Hospital, Surabaya, East Java, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Institute of Tropical Diseases, Universitas Airlangga, Surabaya, East Java, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Postgraduate School of Universitas Airlangga, Surabaya, East Java, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;4&lt;/sup&gt;Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Airlangga, Dr. Soetomo General Academic Hospital, Surabaya, East Java, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;5&lt;/sup&gt;Department of Public Health Sciences Preventive Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, INDONESIA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dewintha Airene Novianti</style></author><author><style face="normal" font="default" size="100%">Puspa Wardhani</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Massive Pleural Effusion with Adenosine Deaminase (ADA) Test Positive and COVID-19 Confirmed: A Case Report</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">ADA test</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">Infectious disease</style></keyword><keyword><style  face="normal" font="default" size="100%">Pleural effusion</style></keyword><keyword><style  face="normal" font="default" size="100%">Pneumonia</style></keyword><keyword><style  face="normal" font="default" size="100%">Tb pleuritis</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">August 2022</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">14</style></volume><pages><style face="normal" font="default" size="100%">450-454</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;A 26-year-old man complained of shortness of breath for 3 days before the hospital admission. The patient had a history of coughing up blood and had consumed alcohol and drugs. Decreased vesicular auscultation and dull percussion in the left lateral pulmo. Laboratory result showed increased neutrophil-lymphocyte ratio C-reactive protein, D-dimer, procalcitonin, ferritin, and decreased albumin level. Pleural fluid analysis indicated the presence of exudate, SARS-CoV-2 PCR positive, and increased ADA level to 43 U/L. Based on the examination results, we suspected that the etiology of the massive pleural effusion was tuberculous pleurisy, particularly due to increased ADA levels. The patient was diagnosed with COVID-19 pneumonia with massive pleural effusion and tuberculous pleurisy. Massive pleural effusion in SARS-CoV-2 infection is rare. Thus, laboratory modalities for massive pleural effusion diagnosis are needed to determine the etiology and effective treatment for the patient. ADA analysis could be considered as an initial examination in patients with pleural effusion during the wait for pleural fluid culture results.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">4</style></issue><work-type><style face="normal" font="default" size="100%">Case Report</style></work-type><accession-num><style face="normal" font="default" size="100%">28</style></accession-num><section><style face="normal" font="default" size="100%">450</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Dewintha Airene Novianti&lt;sup&gt;1&lt;/sup&gt;, Puspa Wardhani &lt;sup&gt;2,*&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Clinical Pathology Specialist Medicine Academic Program, Department of Clinical Pathology, Faculty of Medicine, Universitas Airlangga/Dr. Soetomo General Regional Hospital, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Clinical Pathology, Faculty of Medicine, Universitas Airlangga /Dr. Soetomo General Regional Hospital, Surabaya, INDONESIA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yosua Butar Butar</style></author><author><style face="normal" font="default" size="100%">Puspa Wardhani</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Thalassemia β Major in Confirmed Covid-19 Patient: A Case Report</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">Infection</style></keyword><keyword><style  face="normal" font="default" size="100%">Preventable Death</style></keyword><keyword><style  face="normal" font="default" size="100%">Thalassemia</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">August 2022</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">14</style></volume><pages><style face="normal" font="default" size="100%">445-449</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;The incidence of Thalassemia with confirmed Covid 19 is very rare. The aim of this study is to know the prognosis and evaluate the management of therapy in thalassemia β Mayor patients with COVID-19. This case study describes the progression of Thalassemia β Mayor with COVID 19 starting from how to establish the diagnosis of Thalassemia β Mayor and COVID 19 until how to treat thalassemia β Mayor patients with COVID-19 This case study result describes that COVID 19 aggravates thalassemia β Mayor. Infection can adversely affect thalassemia. Giving Blood transfusions must be done due to anemia in Thalassemia, but it will have an impact on the accumulation of iron in the body which will increase the severity of the infection. The administration of iron-chelation drugs is beneficial for Covid but on the other hand, it is contraindicated in Thalassemia patients.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">4</style></issue><work-type><style face="normal" font="default" size="100%">Case Report</style></work-type><accession-num><style face="normal" font="default" size="100%">27</style></accession-num><section><style face="normal" font="default" size="100%">445</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Yosua Butar Butar&lt;sup&gt;1,*&lt;/sup&gt;, Puspa Wardhani&lt;sup&gt;2&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;F1Clinical Pathology Specialist Medicine Academic Program, Department of Clinical Pathology, Faculty of Medicine, Airlangga University/Dr. Soetomo General Regional Hospital, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Clinical Pathology, Faculty of Medicine, Airlangga University/Dr. Soetomo General Regional Hospital, Surabaya, INDONESIA.&lt;/p&gt;
</style></auth-address></record></records></xml>